Coimbra

• Isatuximab in combination with novel agents in RRMM – Master protocol and control arm Recruiting
  2024-514988-25-00 9 2021-03-31 Cancer
• Isatuximab in combination with SAR445761 (belumosudil) and dexamethasone in relapsed or refractory multiple myeloma Recruiting
  2024-514992-16-00 9 2021-03-31 Cancer
• Isatuximab in combination with evorpacept and dexamethasone in RRMM Recruiting
  2024-514993-38-00 9 2021-03-31 Cancer
• A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembroli … Recruiting
  2024-512671-12-00 10 2021-03-05 Unresectable head and neck squamous cell carcinoma, metastatic head an
• FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting
  2024-510579-40-00 9 2020-10-07 Rhabdoyosarcoma
• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting
  2022-501050-11-01 10 2020-07-13 Acute Lymphoblastic Leukaemia
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended recruitment
  2025-520809-12-00 10 2025-10-16 Diabetic Macular Edema
• A study of Navenibart in Participants with Hereditary Angioedema Ended recruitment
  2025-521660-35-00 5 2025-09-11 Hereditary Angioedema
• A Phase 3, placebo-controlled study to investigate LP352 in children and adults with Developmental and Epileptic Encephalopathies Ended recruitment
  2024-516412-17-00 5 2025-08-26 Developmental and Epileptic Encephalopathies (DEE)
• A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended recruitment
  2024-519773-19-00 5 2025-07-31 Gastroesophageal Junction Adenocarcinoma
• A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended recruitment
  2022-503001-38-01 5 2025-07-08 HR-positive HER-2- negative Breast Cancer
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513282-39-00 5 2025-05-28 Hidradenitis Suppurativa (HS)
• A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended recruitment
  2024-516609-22-00 5 2025-04-15 Primary Sjögren’s Disease
• Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterole … Ended recruitment
  2024-514594-21-00 5 2025-03-13 Heterozygous Familial Hypercholesterolemia
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab … Ended recruitment
  2024-511933-36-00 4 2025-01-02 Diffuse cutaneous systemic sclerosis (dcSSc)
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513208-32-00 5 2024-12-16 Chronic Spontaneous Urticaria
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema … Ended recruitment
  2024-510944-30-00 10 2024-11-22 Diabetic Macular Edema
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended recruitment
  2024-514343-29-00 5 2024-11-19 multiple sclerosis
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, … Ended recruitment
  2023-505739-12-01 5 2024-09-30 Chronic Inducible Urticaria (CINDU)
• A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended recruitment
  2023-503692-24-00 5 2024-09-25 Cutaneous Lupus Erythematosus
• An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancer Ended recruitment
  2023-508219-21-00 5 2024-09-12 BTC - Biliary Tract Cancer
• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive … Ended recruitment
  2024-510908-37-00 5 2024-08-28 KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
• A study to test the effects and safety of riliprubart in people with chronic inflammatory demyelinating polyneuropathy (CIDP) for which the … Ended recruitment
  2023-506503-26-00 5 2024-07-31 Polyneuropathy, Inflammatory Demyelinating, Chronic

Showing 121–144 of 247 trials